Addiss Maldonado Mendez, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: Consultorio Medico El Buen Samaritano Carretera 183, Carretera 183 Km 10.7 Bo. Quemados, San Lorenzo, PR 00754 Phone: 787-736-8436 |
Dr. Luis R Delvalle Galarza, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: Calle Munoz Rivera, Num 5 Norte, San Lorenzo, PR 00754 Phone: 787-736-4071 Fax: 787-736-4071 |
News Archive
Percepta Associates Inc. announces the release of Series Three of its Gene Expression Profiling Life Science Dashboard market research report. Unique to the Percepta report, Series Three offers comparisons to the findings of Series One (February 2007) and Series Two (April 2008).
IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.'s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics' subsidiary located in Italy. The initial term of the distribution agreement is three years.
Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata's electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).
A mom of eight boys, Kim Gudgeon was at her wits' end when she called her family doctor in suburban Chicago to schedule a sick visit for increasingly fussy, 1-year-old Bryce.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 5 days ago